B
BioSapien
Biosapien develops 3D-printed, biocompatible drug delivery implants for localized cancer treatment, reducing chemotherapy side effects and expanding global access to advanced oncology care
About BioSapien
BioSapien, founded in 2018, is a pioneering company in the field of minimally invasive drug delivery platforms, specifically targeting localized cancer treatment. The company has developed a revolutionary 3D printed drug delivery chip designed to deliver medication directly to tumors, thereby minimizing the side effects often associated with systemic chemotherapy. This innovative approach has the potential to treat a wide range of lower gastrointestinal and solid tumors globally, including markets in Europe, the Middle East, and North Africa (MENA) region.
Read full description
BioSapien primarily serves patients suffering from cancer, aiming to improve their quality of life through advanced, biocompatible treatments. The company operates in the healthcare and biotechnology sectors, focusing on cancer care, which saw $208.9 billion in spending in America alone in 2020. BioSapien's business model revolves around the development, manufacturing, and global distribution of its drug delivery technology. The company generates revenue through the sale of its 3D printed drug delivery chips and related medical solutions.
The company recently closed a $1.8 million seed round led by SOSV HIKMA Ventures, with additional investments from Hikma Ventures, Microventures, Infinity Capital Ventures, JPIN VCATS, Side Door Ventures, and other high net worth angels and investors. These funds will be used to advance the development of BioSapien's technology and expand its access to global distribution channels and manufacturing capabilities.
BioSapien's mission is to advance human well-being through innovative solutions, aiming to treat 1 million patients by 2035. The company's vision is to be the leader in biocompatible, minimally invasive cancer treatment, thereby transforming the healthcare landscape.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Diego, United States
- Employees
- 11
- Open positions
- 1
- Dealroom signal
- 64.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, 3D Printing, Biotechnology, Oncology, Chemotherapy, Core AI
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Machine Learning, Deep Learning
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning BioSapien.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Jul 2025 | — | — | Globivest | ↗ |
| SEEDOther financing | Jan 2025 | $7M | $175M | Golden Gate Ventures | ↗ |
Growth signals
Latest recorded traffic for BioSapien is 930 monthly website visits, down 76.8% over the last three months. BioSapien's team declined 8.3% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed20 investors entered at this stage
Indie Bio
RebelBio
SOSV
US National Science Foundation
Harbr
Side Door Ventures- JCJPIN Venture Catalysts
George and Saul
Beni VC- CFCedas Foundation
MicroVentures
Infinity Capital
Hikma Ventures- KGKartik Garg
- NVNorth West Quadrant Ventures ( NWQ Ventures)
Health Engine
Global Ventures
Dara Holdings
Golden Gate Ventures
Globivest
Other known investors3 additional known investors
Hub71
Omar Daniel
Stryde71
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioSapien on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioSapien’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.